Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01190176 · ClinicalTrials.gov registry record · Phase 3
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
NCT01190176 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 34 participants.
The verdict
NCT01190176, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study is intended to provide up to a maximum of four years of annual oncogenic human papillomavirus (HPV) DNA testing and cervical cytology examination for NCT00294047 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV infection at their concluding NCT00294047 study visit. Women who were pregnant at their concluding NCT00294047 study visit may also be included in this study, as no cervical sample could be collected at that visit. The objectives and outcome measures of the primary phase (NCT00294047) are presented in a separate protocol posting.
Interventions
- PROCEDURE Gynaecological follow-up
- BIOLOGICAL Cervarix
- BIOLOGICAL Placebo control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2011-09-12 |
| Est. Completion | 2017-09-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01190176
The ClinicalTrials.gov registry entry for NCT01190176 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gynaecological follow-up is the first listed.
NCT01190176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01190176 about?
NCT01190176 is a clinical study titled "Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects". This study is intended to provide up to a maximum of four years of annual oncogenic human papillomavirus (HPV) DNA testing and cervical cytology examination for NCT00294047 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV infection at their concluding NCT00...
What is the current status of trial NCT01190176?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2011-09-12. Estimated completion is 2017-09-20.
What interventions are being tested in trial NCT01190176?
The interventions under investigation include: Gynaecological follow-up (PROCEDURE), Cervarix (BIOLOGICAL), Placebo control (BIOLOGICAL).
Who is sponsoring clinical trial NCT01190176?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.